Company intelligence / Profile preview

SaNOtize

Vancouver, British Columbia (BC), Canadasanotize.com ↗

Ownership: Private
Development stage: Commercial

Overview

NONS (Nitric Oxide Nasal Spray) has received CE mark in Europe and is being sold in Israel and Bahrain under the name Enovid. It has shown to reduce SARS-CoV-2 viral load in humans.

Therapeutic areas: EndocrinologyInfectious Diseases
Modalities: Nitric oxide-releasing solution
Industry: Biotech

Drug pipeline

4 assets

Nitric oxide-releasing solution

3 more assets in the full pipeline.

Request access →

Partnerships

Glenmark Pharmaceuticals Ltd. (for commercialization in India and Asian markets)

Beyond the preview

Go deeper on SaNOtize.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SaNOtize.

Explore the full profile